{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:19:01Z","timestamp":1790525941408,"version":"4.1.0"},"reference-count":40,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Astra Zeneca Pharma India Ltd","award":["ESR-18-13506"],"award-info":[{"award-number":["ESR-18-13506"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Excess hepatic and pancreatic fat may contribute to hyperglycemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The objective of this study was to examine the effect of dapagliflozin (an SGLT2 inhibitor) on anthropometric profile, liver, and pancreatic fat in patients with type 2 diabetes mellitus (T2DM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is an observational interventional paired study design without a control group. Patients (n\u2005=\u200530) were given dapagliflozin 10 mg\/day (on top of stable dose of metformin and\/or sulfonylureas) for 120 days. Changes in anthropometry (circumferences and skinfold thickness), surrogate markers of insulin resistance, body composition, liver, and pancreatic fat (as measured by magnetic resonance imaging (MRI)-derived proton density fat fraction [FF]) were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After 120 days of treatment with dapagliflozin, a statistically significant reduction in weight, body mass index (BMI), body fat, circumferences, and all skinfold thickness was seen. A statistically significant reduction in blood glucose, glycated hemoglobin A1c, hepatic transaminases, fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR), and postprandial C-peptide was noted, while HOMA-\u03b2, postprandial insulin sensitivity, and fasting adiponectin were statistically significantly increased. There was no change in lean body mass. Compared to baseline there was a statistically significant decrease in mean liver FF (from 15.2% to 10.1%, P\u2005&amp;lt;\u2005.0001) and mean pancreatic FF (from 7.5% to 5.99%, P\u2005&amp;lt;\u2005.0083). Reduction in liver fat was statistically significant after adjustment for change in body weight.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Dapagliflozin, after 120 days of use, reduced pancreatic and liver fat and increased insulin sensitivity in Asian Indian patients with T2DM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgac138","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T17:25:07Z","timestamp":1646846707000},"page":"e2267-e2275","source":"Crossref","is-referenced-by-count":37,"title":["Dapagliflozin Improves Body Fat Patterning, and Hepatic and Pancreatic Fat in Patients With Type 2 Diabetes in North India"],"prefix":"10.1210","volume":"107","author":[{"given":"Amerta","family":"Ghosh","sequence":"first","affiliation":[{"name":"Fortis C-DOC Center of Excellence for Diabetes, Metabolic Diseases, and Endocrinology, New Delhi, India"},{"name":"National Diabetes, Obesity and Cholesterol Foundation (N-DOC), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koel","family":"Dutta","sequence":"additional","affiliation":[{"name":"Fortis C-DOC Center of Excellence for Diabetes, Metabolic Diseases, and Endocrinology, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya Prakash","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Fortis C-DOC Center of Excellence for Diabetes, Metabolic Diseases, and Endocrinology, New Delhi, India"},{"name":"National Diabetes, Obesity and Cholesterol Foundation (N-DOC), New Delhi, India"},{"name":"Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, New Delhi, India"},{"name":"Diabetes Foundation (India), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh","family":"Gupta","sequence":"additional","affiliation":[{"name":"Fortis C-DOC Center of Excellence for Diabetes, Metabolic Diseases, and Endocrinology, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Tyagi","sequence":"additional","affiliation":[{"name":"Fortis C-DOC Center of Excellence for Diabetes, Metabolic Diseases, and Endocrinology, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irshad Ahmad","family":"Ansari","sequence":"additional","affiliation":[{"name":"Fortis C-DOC Center of Excellence for Diabetes, Metabolic Diseases, and Endocrinology, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasantha Kumar","family":"Venugopal","sequence":"additional","affiliation":[{"name":"Mahajan Imaging Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Mahajan Imaging Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra Mohan","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5942-2919","authenticated-orcid":false,"given":"Anoop","family":"Misra","sequence":"additional","affiliation":[{"name":"Fortis C-DOC Center of Excellence for Diabetes, Metabolic Diseases, and Endocrinology, New Delhi, India"},{"name":"National Diabetes, Obesity and Cholesterol Foundation (N-DOC), New Delhi, India"},{"name":"Diabetes Foundation (India), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"issue":"12","key":"2022051722344423400_CIT0001","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S2213-8587(18)30204-3","article-title":"Epidemiology and determinants of type 2 diabetes in south Asia","volume":"6","author":"Hills","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"2022051722344423400_CIT0002","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S2213-8587(18)30199-2","article-title":"Clinical management of type 2 diabetes in south Asia","volume":"6","author":"Misra","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"2022051722344423400_CIT0003","doi-asserted-by":"crossref","first-page":"e0142260","DOI":"10.1371\/journal.pone.0142260","article-title":"Phenotype, body composition, and prediction equations (Indian fatty liver index) for non-alcoholic fatty liver disease in non-diabetic Asian Indians: a case-control study","volume":"10","author":"Bhatt","year":"2015","journal-title":"PLoS One."},{"issue":"12","key":"2022051722344423400_CIT0004","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1007\/s00125-015-3760-z","article-title":"A high-risk phenotype associates with reduced improvement in glycaemia during a lifestyle intervention in prediabetes","volume":"58","author":"Stefan","year":"2015","journal-title":"Diabetologia."},{"issue":"10","key":"2022051722344423400_CIT0005","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2337\/dc10-0856","article-title":"Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes","volume":"33","author":"Lazo","year":"2010","journal-title":"Diabetes Care."},{"issue":"3","key":"2022051722344423400_CIT0006","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3390\/nu11030677","article-title":"Impact of nutritional changes on nonalcoholic fatty liver disease","volume":"11","author":"Perdomo","year":"2019","journal-title":"Nutrients."},{"issue":"3","key":"2022051722344423400_CIT0007","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/oby.2007.110","article-title":"Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition","volume":"16","author":"Pinnick","year":"2008","journal-title":"Obesity (Silver Spring)."},{"issue":"10","key":"2022051722344423400_CIT0008","doi-asserted-by":"crossref","first-page":"e0140447","DOI":"10.1371\/journal.pone.0140447","article-title":"Body fat patterning, hepatic fat and pancreatic volume of non-obese Asian Indians with type 2 diabetes in North India: a case-control study","volume":"10","author":"Misra","year":"2015","journal-title":"PLoS One."},{"issue":"10","key":"2022051722344423400_CIT0009","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1007\/s00125-011-2204-7","article-title":"Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol","volume":"54","author":"Lim","year":"2011","journal-title":"Diabetologia."},{"issue":"4","key":"2022051722344423400_CIT0010","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3390\/nu11040912","article-title":"Changes in pancreatic fat content following diet-induced weight loss","volume":"11","author":"Jiang","year":"2019","journal-title":"Nutrients."},{"issue":"12","key":"2022051722344423400_CIT0011","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S2213-8587(20)30303-X","article-title":"2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial","volume":"8","author":"Al-Mrabeh","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"2022051722344423400_CIT0012","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11892-020-01349-1","article-title":"Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease","volume":"20","author":"Budd","year":"2020","journal-title":"Curr Diab Rep."},{"issue":"1","key":"2022051722344423400_CIT0013","doi-asserted-by":"crossref","first-page":"e49286","DOI":"10.1371\/journal.pone.0049286","article-title":"Non-alcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian Indians in North India","volume":"8","author":"Nigam","year":"2013","journal-title":"PLoS One."},{"issue":"1","key":"2022051722344423400_CIT0014","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1079\/BJN2001382","article-title":"BMI does not accurately predict overweight in Asian Indians in northern India","volume":"86","author":"Dudeja","year":"2001","journal-title":"Br J Nutr."},{"key":"2022051722344423400_CIT0015","first-page":"163","article-title":"Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management","volume":"57","author":"Misra","year":"2009","journal-title":"J Assoc Physicians India."},{"issue":"3","key":"2022051722344423400_CIT0016","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/gast.2002.35354","article-title":"The utility of radiological imaging in nonalcoholic fatty liver disease","volume":"123","author":"Saadeh","year":"2002","journal-title":"Gastroenterology."},{"issue":"2","key":"2022051722344423400_CIT0017","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1006\/mgme.1997.2658","article-title":"Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels","volume":"63","author":"Belfiore","year":"1998","journal-title":"Mol Genet Metab."},{"issue":"5","key":"2022051722344423400_CIT0018","first-page":"917","article-title":"Comparison of the grip strength using the Martin-vigorimeter and the JAMAR-dynamometer: establishment of normal values","volume":"31","author":"Neumann","year":"2017","journal-title":"In Vivo."},{"issue":"1","key":"2022051722344423400_CIT0019","first-page":"45","article-title":"Ultrasonographic diagnosis of fatty liver [article in Chinese]","volume":"85","author":"Tam","year":"1986","journal-title":"Taiwan Yi Xue Hui Za Zhi."},{"issue":"6","key":"2022051722344423400_CIT0020","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/dia.2010.0198","article-title":"Consensus dietary guidelines for healthy living and prevention of obesity, the metabolic syndrome, diabetes, and related disorders in Asian Indians","volume":"13","author":"Misra","year":"2011","journal-title":"Diabetes Technol Ther."},{"issue":"1","key":"2022051722344423400_CIT0021","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/dia.2011.0111","article-title":"Consensus physical activity guidelines for Asian Indians","volume":"14","author":"Misra","year":"2012","journal-title":"Diabetes Technol Ther."},{"issue":"4","key":"2022051722344423400_CIT0022","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5114\/ceh.2020.102173","article-title":"SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review","volume":"6","author":"Dwinata","year":"2020","journal-title":"Clin Exp Hepatol."},{"issue":"3","key":"2022051722344423400_CIT0023","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2022051722344423400_CIT0024","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/dom.14004","article-title":"Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes","volume":"22","author":"Johansson","year":"2020","journal-title":"Diabetes Obes Metab."},{"issue":"5","key":"2022051722344423400_CIT0025","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care."},{"issue":"2","key":"2022051722344423400_CIT0026","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab."},{"issue":"6","key":"2022051722344423400_CIT0027","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"J Diabetes Investig."},{"issue":"9","key":"2022051722344423400_CIT0028","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia."},{"issue":"8","key":"2022051722344423400_CIT0029","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.diabres.2018.05.017","article-title":"Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus","volume":"142","author":"Kurinami","year":"2018","journal-title":"Diabetes Res Clin Pract."},{"issue":"1","key":"2022051722344423400_CIT0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41574-021-00573-3","article-title":"Metabolic implications of pancreatic fat accumulation","volume":"18","author":"Wagner","year":"2022","journal-title":"Nat Rev Endocrinol."},{"issue":"11","key":"2022051722344423400_CIT0031","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1210\/clinem\/dgaa435","article-title":"Pancreatic steatosis associates with impaired insulin secretion in genetically predisposed individuals","volume":"105","author":"Wagner","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2022051722344423400_CIT0032","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s00125-015-3544-5","article-title":"Pancreatic adipose tissue infiltration, parenchymal steatosis and beta cell function in humans","volume":"58","author":"Begovatz","year":"2015","journal-title":"Diabetologia."},{"issue":"1","key":"2022051722344423400_CIT0033","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","article-title":"Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study","volume":"20","author":"Gaborit","year":"2021","journal-title":"Cardiovasc Diabetol."},{"issue":"10","key":"2022051722344423400_CIT0034","doi-asserted-by":"crossref","first-page":"154324","DOI":"10.1016\/j.metabol.2020.154324","article-title":"Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice","volume":"111","author":"Wei","year":"2020","journal-title":"Metabolism."},{"issue":"11","key":"2022051722344423400_CIT0035","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jdiacomp.2018.08.001","article-title":"Body fat, metabolic syndrome and hyperglycemia in South Asians","volume":"32","author":"Misra","year":"2018","journal-title":"J Diabetes Complications."},{"issue":"6","key":"2022051722344423400_CIT0036","doi-asserted-by":"crossref","first-page":"467","DOI":"10.5551\/jat.40873","article-title":"Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes","volume":"25","author":"Sugiyama","year":"2018","journal-title":"J Atheroscler Thromb."},{"issue":"5","key":"2022051722344423400_CIT0037","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/1753-0407.12402","article-title":"Increased grip strength with sodium-glucose cotransporter 2","volume":"8","author":"Sano","year":"2016","journal-title":"J Diabetes."},{"issue":"1","key":"2022051722344423400_CIT0038","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41387-019-0098-5","article-title":"Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study","volume":"9","author":"Tang","year":"2019","journal-title":"Nutr Diabetes."},{"issue":"7","key":"2022051722344423400_CIT0039","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.curtheres.2017.07.002","article-title":"Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study","volume":"87","author":"Tobita","year":"2017","journal-title":"Curr Ther Res Clin Exp."},{"issue":"6","key":"2022051722344423400_CIT0040","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac138\/43225675\/dgac138.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/6\/e2267\/43739287\/dgac138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/6\/e2267\/43739287\/dgac138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T22:39:11Z","timestamp":1652827151000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/6\/e2267\/6545841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3,9]]},"published-print":{"date-parts":[[2022,5,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac138","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,3,9]]}}}